Diagnostic Platform
“Our proprietary microbial biomarkers are non-invasive, biologically relevant, and disease-specific.”
MicroSigX’s biomarker discovery platform utilizes in-depth metagenomic analysis of large human microbial datasets and in-house proprietary machine-learning approaches to identify microbiome signatures specific to different human diseases with high accuracy
1. Advanced sequencing and proprietary algorithms
MicroSigX’s core diagnostic technology transforms metagenomic-sequencing derived-microbial signals into proprietary algorithms to predict risk of diseases
2. At-home stool sample collection
Simple sampling method preserves quality of microbial community profile at room temperature, ensuring convenient storage and transport
3. Development of PCR-based technologies for disease risk assessment
Transforming untargeted metagenomic detection into targeted-PCR approaches and optimizing PCR technologies for maximum accuracy
4. Discovery, validation and real-life testing
MicroSigX’s patented core PCR and metagenomics technologies have been extensively validated, demonstrating unparalleled performance in multiple validation and real-life settings. Some of these technologies are poised to enter clinical trials for regulatory approval as first-in-class in vitro diagnostics.
